Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/51054

TítuloSelective activation of protein kinase C-δ and -ɛ by 6,11,12,14-tetrahydroxy-abieta-5,8,11,13-tetraene-7-one (coleon U)
Autor(es)Coutinho, Isabel
Pereira, G.
Simões, M. F.
Côrte-Real, Manuela
Gonçalves. Jorge
Saraiva, L.
Palavras-chaveColeon U
Selective PKC activator
PKC-delta
PKC-epsilon
Apoptosis
Yeast
PKC-δ
PKC-ε
Data2009
EditoraPergamon-Elsevier Science Ltd
RevistaBiochemical Pharmacology
Resumo(s)6,11,12,14-tetrahydroxy-abieta-5,8,11,13-tetraene-7-one (coleon U) is a diterpene compound isolated from Plectranthus grandidentatus with an antiproliferative effect on several human cancer cell lines. Herein, we studied the modulatory activity of coleon U on individual isoforms of the three protein kinase C (PKC) subfamilies, classical (cPKC-α and -βI), novel (nPKC-δ and -ɛ) and atypical (aPKC-ζ), using a yeast PKC assay. The results showed that, whereas the PKC activator phorbol-12-myristate-13-acetate (PMA) activated every PKC tested except aPKC, coleon U had no effect on aPKC and cPKCs. Besides, the effect of coleon U on nPKCs was higher than that of PMA. This revealed that coleon U was a potent and selective activator of nPKCs. The isoform-selectivity of coleon U for nPKC-δ and -ɛ was confirmed using an in vitro PKC assay. Most importantly, while PMA activated nPKCs inducing an isoform translocation from the cytosol to the plasma membrane and a G2/M cell cycle arrest, coleon U induced nPKCs translocation to the nucleus and a metacaspase- and mitochondrial-dependent apoptosis. This work therefore reconstitutes in yeast distinct subcellular translocations of a PKC isoform and the subsequent distinct cellular responses reported for mammalian cells. Together, our study identifies a new isoform-selective PKC activator with promising pharmacological applications. Indeed, since coleon U has no effect on cPKCs and aPKC, recognised as anti-apoptotic proteins, and selectively induces an apoptotic pathway dependent on nPKC-δ and -ɛ activation, it represents a promising compound for evaluation as an anti-cancer drug.
TipoArtigo
URIhttps://hdl.handle.net/1822/51054
DOI10.1016/j.bcp.2009.04.026
ISSN0006-2952
Arbitragem científicayes
AcessoAcesso aberto
Aparece nas coleções:DBio - Artigos/Papers

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Coutinho et al 2015.pdf664,08 kBAdobe PDFVer/Abrir

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID